Targeting VE-PTP phosphatase protects the kidney from diabetic injury.

Published

Journal Article

Diabetic nephropathy is a leading cause of end-stage kidney failure. Reduced angiopoietin-TIE2 receptor tyrosine kinase signaling in the vasculature leads to increased vascular permeability, inflammation, and endothelial cell loss and is associated with the development of diabetic complications. Here, we identified a mechanism to explain how TIE2 signaling is attenuated in diabetic animals. Expression of vascular endothelial protein tyrosine phosphatase VE-PTP (also known as PTPRB), which dephosphorylates TIE2, is robustly up-regulated in the renal microvasculature of diabetic rodents, thereby reducing TIE2 activity. Increased VE-PTP expression was dependent on hypoxia-inducible factor transcriptional activity in vivo. Genetic deletion of VE-PTP restored TIE2 activity independent of ligand availability and protected kidney structure and function in a mouse model of severe diabetic nephropathy. Mechanistically, inhibition of VE-PTP activated endothelial nitric oxide synthase and led to nuclear exclusion of the FOXO1 transcription factor, reducing expression of pro-inflammatory and pro-fibrotic gene targets. In sum, we identify inhibition of VE-PTP as a promising therapeutic target to protect the kidney from diabetic injury.

Full Text

Duke Authors

Cited Authors

  • Carota, IA; Kenig-Kozlovsky, Y; Onay, T; Scott, R; Thomson, BR; Souma, T; Bartlett, CS; Li, Y; Procissi, D; Ramirez, V; Yamaguchi, S; Tarjus, A; Tanna, CE; Li, C; Eremina, V; Vestweber, D; Oladipupo, SS; Breyer, MD; Quaggin, SE

Published Date

  • April 1, 2019

Published In

Volume / Issue

  • 216 / 4

Start / End Page

  • 936 - 949

PubMed ID

  • 30886059

Pubmed Central ID

  • 30886059

Electronic International Standard Serial Number (EISSN)

  • 1540-9538

Digital Object Identifier (DOI)

  • 10.1084/jem.20180009

Language

  • eng

Conference Location

  • United States